BioAge Labs (BIOA) CMO sells 7,433 shares after option exercise sale

Rhea-AI Filing Summary

BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported option exercises and a share sale. On January 2, 2026, he exercised stock options to acquire 5,433 common shares at $4.11 per share and 2,000 common shares at $6.57 per share. On the same day he sold 7,433 common shares at a weighted average price of $12.8468 per share, with individual sale prices ranging from $12.571 to $13.242. Following these transactions, he directly held no shares of common stock but continued to hold stock options, including 16,303 options at $4.11 and 7,383 options at $6.57. The activity was carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024.

Insider Trade Summary

Net Seller: 7,433 shares ($95,490)

Net Sell 5 txns

Insider RUBIN PAUL D

Role Chief Medical Officer

Sold 7,433 shs ($95K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	5,433	$0.00	--
Exercise	Stock Option (Right to Buy)	2,000	$0.00	--
Exercise	Common Stock	5,433	$4.11	$22K
Exercise	Common Stock	2,000	$6.57	$13K
Sale	Common Stock	7,433	$12.8468	$95K

Holdings After Transaction: Stock Option (Right to Buy) — 16,303 shares (Direct); Common Stock — 5,433 shares (Direct)

Footnotes (1)

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.571 to $13.242 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBIN PAUL D

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		M(1)		5,433	A	$4.11	5,433	D
Common Stock	01/02/2026		M(1)		2,000	A	$6.57	7,433	D
Common Stock	01/02/2026		S(1)		7,433	D	$12.8468(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.11	01/02/2026		M(1)			5,433	(3)	06/30/2030	Common Stock	5,433	$0	16,303	D
Stock Option (Right to Buy)	$6.57	01/02/2026		M(1)			2,000	(4)	05/28/2032	Common Stock	2,000	$0	7,383	D

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.571 to $13.242 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.

4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BIOA's Chief Medical Officer report?

BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported exercising stock options and selling common shares. He acquired 7,433 common shares through option exercises and then sold 7,433 common shares on January 2, 2026.

How many BioAge Labs (BIOA) shares did the CMO sell and at what price?

The Chief Medical Officer sold 7,433 common shares of BioAge Labs, Inc. at a weighted average price of $12.8468 per share. The individual sale prices ranged from $12.571 to $13.242 per share.

What stock options did the BIOA CMO exercise in this Form 4 filing?

On January 2, 2026, he exercised stock options covering 5,433 shares of common stock at an exercise price of $4.11 per share and 2,000 shares at an exercise price of $6.57 per share.

How many stock options does the BioAge Labs (BIOA) CMO still hold after these transactions?

After the reported transactions, he held 16,303 stock options with a $4.11 exercise price and 7,383 stock options with a $6.57 exercise price, all reported as directly owned.

Did the BIOA CMO still own any common shares after the reported sale?

No. The filing shows that after selling 7,433 common shares on January 2, 2026, the amount of directly owned common stock reported was 0 shares.

Was the BioAge Labs (BIOA) insider transaction under a Rule 10b5-1 plan?

Yes. A footnote states that the transaction reported was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

What is noted about vesting of the CMOs stock options at BIOA?

One option is reported as fully vested, having become fully vested on May 11, 2024. Another option award vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and subsequent tranches vesting monthly, subject to continued service.